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Telaprevir (TVR)-based triple therapy in patients (pts) with chronic hepatitis C (HCV) in daily practice in Germany is investigated
in this non-interventional study. Aims are the evaluation of the implementation of futility rules, as well as safety and efficacy of
TVR-based therapy.This prospective, multi-center study investigates TVR-based therapy in therapy-naı ¨ve and pretreated pts with
genotype 1 chronic HCV in Germany, including pts with HIV co-infection. Patients are treated with a combination of TVR,
ribavirin and peg-interferon. This interim analysis includes data from the first 100 pts (12.5% of the planned total) at 32 sites
completing 12 weeks (W) of treatment. 66% of pts were pretreated for HCV. 36.4% of pts with pre-treatment were prior
relapsers and 30.3% null or partial responders. Cirrhosis was present in 11% of all pts at baseline. HCV RNA levels below 800.000
IU/ml at baseline were present in 50% of pts. 67% of pts showed rapid virological response (RVR, undetectable HCV RNA at W4).
Adherence to the futility rule (treatment stop if HCV-RNA 1000 IU/ml at W4) was 100% (N9). At W12, 91.4% of pts had
undetectable HCV RNA. 57.7% of therapy-naı ¨ve pts and 86.4% of previous relapsers were HCV-RNA negative at both W4 and 12
(70.8% in total). Only one patient achieving RVR at W4 suffered a virologic breakthrough. Nearly all pts (99%) had adverse events
(AE) during the first 12W, 6% reported serious adverse events (SAE). AEs were mostly mild (63.9%) or moderate (34.6%) and
frequently mentioned dry skin/pruritus (54%), gastrointestinal disorders (48%), anorectal discomfort (30%), rash (29%) and
anemia (23%). Rash was mostly rated as mild or moderate (97.1%). An Hb decreaseB12 g/dl (female) orB13 g/dl (male) was
reported in 87% of pts. Mean Hb levels decreased from 14.8 g/dl at baseline to 10.6 g/dl at W12; Hb levelsB8.5 g/dl at any
time within the first 12W of treatment were present in 11% of anemia cases and 6.6% required transfusion. Only one patient
received erythropoietin treatment. 2 cases each of anemia and rash were considered as SAE. These interim results suggest that
TVR-based triple-therapy is efficient against GT1 chronic hepatitis C in a real life setting. Adherence to futility rules was
confirmed in all patients. As observed in clinical trials, adverse events were reported frequently, including anemia and rash.
As more data become available, results will be updated.
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